JPMA President Kinoshita speaks at a panel organized by "Endpoints News" in the U.S. Communicating the appeal of the Japanese pharmaceutical market to the global audience
JPMA President Kenshi Kinoshita recently participated in a panel discussion hosted by Endpoints News, a U.S.-based media outlet for the biopharmaceutical industry.
Endpoints News is a U.S.-based news media outlet specializing in the biopharmaceutical industry and provides information on industry trends, policies, and corporate strategies to pharmaceutical companies, investors, academia, and others. Endpoints News provides in-depth information on industry trends, policies, and corporate strategies to pharmaceutical companies, investors, and academia. This year's panel was conducted in English and was attended by over 1,000 online participants from major U.S. pharmaceutical companies, bioventures, and research institutions.
Speakers:
Christopher Dahl, President, Gemmab Inc.
Kenshi Kinoshita, President, Japan Pharmaceutical Manufacturers Association
Mr. Arsalan Arif, Founder and Publisher/Moderator, Endpoints News
The theme of this year's session was "The Attractiveness and Potential of the Japanese Pharmaceutical Market. He introduced the current situation and future prospects of the Japanese system, regulations, and drug prices from a global perspective. Mr. Christopher Dahl, head of Gemmab K.K., as the head of the Japanese subsidiary, talked about business opportunities in the Japanese market and his desire to bring innovative drugs to Japanese patients.
As a representative of the industry association, President Kinoshita gave a detailed Explanation of the current status and direction of reform of Japan's NHI drug pricing system and regulatory process, as well as the international value of the Japanese market, and encouraged audience understanding and interest in the Japanese market.
This panel provided a valuable opportunity to communicate the appeal of Japan's pharmaceutical industry to the rest of the world, and is expected to promote international collaboration and future investment.
Through its 12 committees and 6 specialized organizations (including the Policy Research Institute), JPMA is also working on regulatory responses, including the Pharmaceutical Affairs Law, and proposals for reform of the NHI drug price system. We will continue to further strengthen our activities to deliver innovation to patients in Japan and from Japan to patients around the world.
(Chie Honda, Director of Public Relations)